Cargando…

A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid

BACKGROUND: Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) is a novel treatment option for gemcitabine-pretreated metastatic pancreatic adenocarcinoma (PAC) patients, but real-world evidence is rare. Our aim was to determine the effectiveness and tolerability of this reg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kieler, Markus, Unseld, Matthias, Bianconi, Daniela, Scheithauer, Werner, Prager, Gerald W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640066/ https://www.ncbi.nlm.nih.gov/pubmed/31360237 http://dx.doi.org/10.1177/1758835919853196

Ejemplares similares

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
por: Verbruggen, Lise, et al.
Publicado: (2023)

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Park, Se Jun, et al.
Publicado: (2021)

Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC
por: Bianconi, Daniela, et al.
Publicado: (2020)

Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
por: Kieler, Markus, et al.
Publicado: (2020)

Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer
por: Kieler, Markus, et al.
Publicado: (2017)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
por: Chun, Jung Won, et al.
Publicado: (2022)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
por: Chen, Li-Tzong, et al.
Publicado: (2019)

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
por: Garufi, C, et al.
Publicado: (2003)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior
por: Bianconi, Daniela, et al.
Publicado: (2022)

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
por: Barone, C, et al.
Publicado: (2007)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
por: Teufel, Andreas, et al.
Publicado: (2004)

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
por: Bianconi, Daniela, et al.
Publicado: (2017)

Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
por: Kieler, Markus, et al.
Publicado: (2018)

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
por: Fischel, J-L, et al.
Publicado: (2001)

Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
por: Abughanimeh, Omar K, et al.
Publicado: (2017)

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
por: Yoo, Changhoon, et al.
Publicado: (2019)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
por: Balendran-Braun, Sukirthini, et al.
Publicado: (2021)

FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial
por: Zhang, Xiaowei, et al.
Publicado: (2022)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
por: Souglakos, J, et al.
Publicado: (2012)

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
por: Souglakos, J, et al.
Publicado: (2006)

Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2002)

Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pancreatic Adenocarcinoma
por: Dacie, Ruth, et al.
Publicado: (2020)

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
por: Park, H.S., et al.
Publicado: (2021)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study
por: Miki, Masami, et al.
Publicado: (2022)

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
por: Kawakami, Takeshi, et al.
Publicado: (2023)

Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer
por: Ikezawa, Kenji, et al.
Publicado: (2021)

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(†)
por: Obermannová, R., et al.
Publicado: (2016)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
por: Procaccio, Letizia, et al.
Publicado: (2023)

A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid
por: Correale, P, et al.
Publicado: (2003)

5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
por: Kerr, D. J.
Publicado: (1989)

Integrins in the Spotlight of Cancer
por: Bianconi, Daniela, et al.
Publicado: (2016)

Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
por: Kuehr, Thomas, et al.
Publicado: (2004)

Irinotecan plus fluorouracil‐based regimen as second or third‐line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma
por: Wang, Xi, et al.
Publicado: (2015)

Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer
por: Jonker, D., et al.
Publicado: (2006)

SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment
por: Bianconi, Daniela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_40gm0m2p5edhva35vu4m8buune